212377 Therapeutic effects of marine collagen peptides on Chinese patients with type 2 diabetes mellitus and hypertension

Monday, November 9, 2009

Zhu Cuifeng, 4328011970112710 , Department of nutrition, peking University ShenZhen Hospital, Shenzhen City, China
Background and aims: The study aimed to examine the effects of marine collagen peptides (MCP) on glucose and lipid metabolism in Chinese patients with type 2 diabetes mellitus (T2DM) and hypertension.

Methods and results: A total of 100 patients with T2DM and hypertension and 50 healthy subjects were recruited and the patients were randomized into treatment and control groups. All patients received regular medicines for control of hyperglycemia and hypertension. The patients in treatment group received additional 13 g MCP daily for 3 months. Their blood pressures, glucose and lipid metabolism and serum high sensitivity C-reactive protein (hs-CRP), cytochrome P450 (CYP450), nitric oxide (NO), bradykinin, prostacycline (PGI2), creatinine (CR), uric acid (UA), and adipokines were measured longitudinally before, 1.5 and 3 months after treatment. MCP treatments significantly reduced the levels of fasting blood glucose (FBG), GHbA1c, diastolic blood pressure (DBP), mean arterial pressure (MAP), and serum creatinine (CR), but increased insulin sensitivity index (ISI) and insulin secretion index (IS). The levels of FBG, fasting insulin (FI), GHbA1c, insulin sensitivity index (ISI), and CR in treatment group were significantly lower than that of patient controls (p<0.05 or 0.01). Similarly, MCP treatment decreased the levels of serum TG, TC, LDL, free fatty acids (FFA), CYP450, NO, and PGI2, but increased HDL, bradykinin and adiponectin, which were significantly lower or higher than that of patient controls, respectively (p<0.01).

Conclusions: MCP treatment improved glucose and lipid metabolism, insulin resistance, renal function and hypertension management in diabetic and hypertensive patients.

Learning Objectives:
Background and aims: The study aimed to examine the effects of marine collagen peptides (MCP) on glucose and lipid metabolism in Chinese patients with type 2 diabetes mellitus (T2DM) and hypertension. Methods and results: A total of 100 patients with T2DM and hypertension and 50 healthy subjects were recruited and the patients were randomized into treatment and control groups. All patients received regular medicines for control of hyperglycemia and hypertension. The patients in treatment group received additional 13 g MCP daily for 3 months. Their blood pressures, glucose and lipid metabolism and serum high sensitivity C-reactive protein (hs-CRP), cytochrome P450 (CYP450), nitric oxide (NO), bradykinin, prostacycline (PGI2), creatinine (CR), uric acid (UA), and adipokines were measured longitudinally before, 1.5 and 3 months after treatment. MCP treatments significantly reduced the levels of fasting blood glucose (FBG), GHbA1c, diastolic blood pressure (DBP), mean arterial pressure (MAP), and serum creatinine (CR), but increased insulin sensitivity index (ISI) and insulin secretion index (IS). The levels of FBG, fasting insulin (FI), GHbA1c, insulin sensitivity index (ISI), and CR in treatment group were significantly lower than that of patient controls (p<0.05 or 0.01). Similarly, MCP treatment decreased the levels of serum TG, TC, LDL, free fatty acids (FFA), CYP450, NO, and PGI2, but increased HDL, bradykinin and adiponectin, which were significantly lower or higher than that of patient controls, respectively (p<0.01). Conclusions: MCP treatment improved glucose and lipid metabolism, insulin resistance, renal function and hypertension management in diabetic and hypertensive patients.

Keywords: Chronic Diseases, Food and Nutrition

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: Research fields 1. infants and young children, adolescents, pregnant women, the elderly and various types of special occupational groups such as health or sub-health population nutrition and health; 2. obesity, diabetes, hyperuricemia, malignant diseases such as nutrition and health care groups and clinical nutrition therapy and the corresponding research, teaching. The main study and work notes: 1. 2006.08|2009.06 Peking University School of Public Health, Nutrition and Food Hygiene Department, Ph.D; 2. 2000.06-now, Transferred to Peking University Shenzhen Hospital Nutrition Division, Branch Director, Chief physician(Deputy director of Physicians, Competent technicians) 3. 1999.08|2002.07, Guangxi Medical University School of Public Health, Nutrition and Food Hygiene Department, Master; 4. 1993.12|2000.06, Transferred to the First Affiliated Hospital of Sun Yat-sen University Endocrine Division, Competent technicians; 5. 1991.09|1994.07, Guangzhou Medical College, students 6. 1989.07|1993.12, Assigned to the school in Guangdong Province, Guangzhou Institute psychiatric hospital treatment, technicians; 7. 1986.09|1989.07, Chenzhou City in Hunan Province Higher Medical College, students.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

See more of: A Cornucopia of Student Research in Public Health
See more of: APHA-Student Assembly